Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of AAV2/8-hCARp.hCNGB3 gene therapy in CNGB3 achromatopsia
2016-003856-59Phase 2Unknown
- Sponsor
- MeiraGTx
- Start
- Feb 2017
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entacingene turiparvovec in achromatopsia (ACHM), sponsored by MeiraGTx. Primary endpoint: Long-term safety of subretinal administration of the ATIMP. Status: unknown.
02
Drugs
entacingene turiparvovec
03
Conditions
achromatopsia (ACHM)
Beyond the preview
Go deeper on 2016-003856-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003856-59.